Detecting Förster resonance energy transfer in living cells by conventional and spectral flow cytometry.

Autor: Henderson J; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA., Havranek O; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.; BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic.; Department of Hematology, Charles University and General University Hospital, Prague, Czech Republic., Ma MCJ; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA., Herman V; BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic.; Department of Hematology, Charles University and General University Hospital, Prague, Czech Republic., Kupcova K; BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic., Chrbolkova T; BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic., Pacheco-Blanco M; BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic., Wang Z; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA., Comer JM; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA., Zal T; Department of Leukemia, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA., Davis RE; Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Cytometry. Part A : the journal of the International Society for Analytical Cytology [Cytometry A] 2022 Oct; Vol. 101 (10), pp. 818-834. Date of Electronic Publication: 2021 Jun 24.

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.

Autor: Ma MCJ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Tadros S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Bouska A; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE., Heavican T; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE., Yang H; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Deng Q; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Moore D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE., Akhter A; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB., Hartert K; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE., Jain N; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Showell J; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Ghosh S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Street L; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB., Davidson M; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB., Carey C; Northern Institute for Research, Newcastle University, Newcastle upon Tyne, England., Tobin J; Diamantina Institute, University of Queensland, QLD., Perumal D; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Vose JM; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE., Lunning MA; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE., Sohani AR; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA., Chen BJ; Department of Pathology, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, MA., Buckley S; Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE., Nastoupil LJ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Davis RE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Westin JR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Fowler NH; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Parekh S; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Gandhi M; Diamantina Institute, University of Queensland, QLD., Neelapu S; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Stewart D; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB., Bhalla K; Department of Pathology, Brigham and Womens Hospital, Boston, MA., Iqbal J; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE., Greiner T; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE., Rodig SJ; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Mansoor A; Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB., Green MR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX. mgreen5@mdanderson.org.

Publikováno v: Haematologica [Haematologica] 2022 Mar 01; Vol. 107 (3), pp. 690-701. Date of Electronic Publication: 2022 Mar 01.

Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.

Autor: Nishida Y; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao R; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heese LE; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Akiyama H; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel S; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger AM; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Jacamo RO; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kojima K; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan., Ma MCJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ruvolo VR; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chachad D; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Devine W; Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, MA, USA., Lindquist S; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Porco JA Jr; Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, MA, USA., Whitesell L; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada., Andreeff M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org., Ishizawa J; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jishizawa@mdanderson.org.

Publikováno v: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2469-2481. Date of Electronic Publication: 2021 Jun 14.

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.

Autor: Mondello P; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York., Tadros S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Teater M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York., Fontan L; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York., Chang AY; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Jain N; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang H; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Singh S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ying HY; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York., Chu CS; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York., Ma MCJ; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Toska E; Department of Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York., Alig S; Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany., Durant M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Ghosh S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mottok A; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Nastoupil L; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Weigert O; Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany., Inghirami G; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York., Baselga J; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York., Younes A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dogan A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Scheinberg DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Roeder RG; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York., Melnick AM; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York. mgreen5@mdanderson.org amm2014@med.cornell.edu., Green MR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. mgreen5@mdanderson.org amm2014@med.cornell.edu.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer discovery [Cancer Discov] 2020 Mar; Vol. 10 (3), pp. 440-459. Date of Electronic Publication: 2020 Jan 08.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Autor: Ishizawa J; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., Zarabi SF; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada., Davis RE; The University of Texas MD Anderson Cancer Center; Department of Lymphoma and Myeloma, Houston, TX 77030, USA., Halgas O; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada., Nii T; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., Jitkova Y; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Zhao R; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., St-Germain J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Heese LE; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., Egan G; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Ruvolo VR; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., Barghout SH; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada., Nishida Y; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., Hurren R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Ma W; The University of Texas MD Anderson Cancer Center, Bioinformatics and Comp Biology, Houston, TX 77030, USA., Gronda M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Link T; The University of Texas MD Anderson Cancer Center, Genomic Medicine, Houston, TX 77030, USA., Wong K; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada., Mabanglo M; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada., Kojima K; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA; Saga University, Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga 849-8501, Japan., Borthakur G; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA., MacLean N; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Ma MCJ; The University of Texas MD Anderson Cancer Center; Department of Lymphoma and Myeloma, Houston, TX 77030, USA., Leber AB; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada., Houry W; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada., Kantarjian H; The University of Texas MD Anderson Cancer Center; Department of Leukemia, Houston, TX 77030, USA., Stogniew M; Oncoceutics, Inc., Philadelphia, PA 19104, USA., Raught B; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada., Pai EF; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada., Schimmer AD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada. Electronic address: aaron.schimmer@uhn.ca., Andreeff M; The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center; Department of Leukemia, Houston, TX 77030, USA. Electronic address: mandreef@mdanderson.org.

Publikováno v: Cancer cell [Cancer Cell] 2019 May 13; Vol. 35 (5), pp. 721-737.e9. Date of Electronic Publication: 2019 May 02.